MedTrace Logo

Mediators of Kidney-Bone Communication in Childhood

NCT02040740 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2019-11-25

No results posted yet for this study

Summary

An identified hormone linking bone and kidney function is Fibroblast Growth Factor-23 (FGF23). Data on the variation of FGF23 levels for bone and mineral metabolism in children are scarce. Currently it is assumed that meeting mineral requirements for the skeleton serves the body's overall needs. However, it is not clear as to whether this is true, particularly with growth. The contribution of dietary factors directly linked with the bone/kidney axis through measurement of intake (via 24hr recall) and kidney nutrient clearance (via serum and urinary analysis) will be included in investigations. Findings will serve as a springboard for delineating more specific mechanisms by which these systems become disordered and are influenced by diet. It is expected that adequacy of nutrients known to have a central role in bone function will optimize the hormonal milieu through crosstalk with the kidney.

This effort will allow ongoing investigation in detecting and treating disturbances in mineral metabolism related to kidney disease, specifically in the pediatric population and broaden the understanding of kidney disease itself, as well as that of chronic diseases in which kidney health is of importance, such as diabetes and osteoporosis. Findings of this research may stress the importance of achieving dietary adequacy essential for establishing optimal body composition trajectories, particularly puberty.

Conditions

  • Fasting Blood Measures
  • Body Scans

Sponsors & Collaborators

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • Krista Casazza, PhD, RD · UAB, Nutrition Sciences

  • Orlando M Gutierrez, MD · UAB, Department of Medicine

  • Lynae J Hanks, PhD, RD · UAB, Department of Medicine

  • Ambika P Ashraf, MD · Children's of Alabama, Pediatric Endocrinology

Eligibility

Min Age
7 Years
Max Age
12 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02040740 on ClinicalTrials.gov